E SciSparc Might Become The Next GW Pharmaceuticals

Sci-110: Alzheimer's

Alzheimer’s disease is the most common form of dementia, a progressive brain disease that slowly destroys memories and thinking skills. Symptoms usually start with difficulty remembering new information and, in advanced stages, symptoms include confusion, mood, and behavior changes, and inability to care for one’s self and perform basic life tasks. Worldwide about 50 million people have some form of dementia,

The disease:

  • ranks as the third leading cause of death, after heart disease and cancer,
  • affects approximately 5.7 million people in the U.S. currently (200,000 people under age 65 have early-onset Alzheimer’s disease) and that number is projected to triple to 16 million by 2050,
  • doubles about every five years after age 65 and, after age 85, the risk reaches nearly 50%,
  • will adversely affect Latino and African American populations as their "senior citizens" will grow 224% and 114%, respectively, by 2030, compared to a 65% growth rate for non-Latino white Americans and
  • will affect African Americans twice as likely as white Americans and Latinos by 1.5 times.

According to research and consulting firm, GlobalData, disease-modifying treatments for Alzheimer’s Disease as well as novel symptomatic therapies with innovative mechanisms of action will enter the arena between now and 2030.

  • Symptomatic therapies such as Lundbeck’s LuAE-58054 and Forum’s EVP-6124 are already in the pipeline and
  • Biogen’s aducanumab; Eli Lilly’s solanezumab; Roche’s gantenerumab and crenezumab; Merck’s MK-8931 and AstraZeneca/Eli Lilly’s AZD-3293 are in development.
  • Namenda, Aricept, and Exelon, the current AD drug market leaders, will maintain strong shares throughout the forecast period but see their combined sales fall annually with Namenda and Aricept having recently lost patent exclusivity.

Given the aforementioned, Data Bridge Market Research expects that the Alzheimer’s disease treatment market size will grow at a CAGR of 8.29% between now and 2027 and reach US$6.65B by then. Were SciSprac's SCI-110 product eventually approved by the FDA a modest 0.5% share of that market would equate to potential revenue of $33.3M annually although such a possibility would not materialize until the end of the decade at the earliest.

 

SCI-160: Pain

Pain is a disturbing sensory and emotional sensation that results from tissue damage or disease ranging from acute pain for the short term to chronic pain for the long term. A variety of drugs are used to manage pain resulting from inflammation in response to tissue damage, chemical agents (pathogens), or nerve damage (neuropathic pain). Most drugs act by binding to protein targets on cell membranes and affecting biochemical processes of the body.

The rise in the geriatric population is the major factor that drives the growth of the global pain management drugs market as aged people are more prone to suffer from joint pain and other chronic conditions as well as the surge in the prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis. In addition, the rise in the number of surgical procedures and an increase in healthcare expenditure are expected to fuel growth of the pain management drugs market.

Some of the key players operating in the market include Novartis, Eli Lilly, Abbott Laboratories, Endo Health Solutions, Purdue Pharma, Pfizer, Mylan, Merck, Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen, Bayer, Bristol-Myers Squibb, Valeant Pharmaceuticals, Boehringer Ingelheim, Sorrento Therapeutics, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

According to Allied Market Research, the global pain management drugs market was valued at US$71.4B in 2019 and is projected to reach US$91.6B by 2027, registering a CAGR of 3.8% from 2020 to 2027. Were SciSprac's SCI-110 product eventually approved by the FDA a modest 0.5% share of that market by SciSparc would equate to potential revenue of approximately $45.8M annually although such a possibility would not materialize until the end of the decade at the earliest.

SCI-210: Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a heritable and polygenic neurodevelopmental lifelong disorder that typically emerges as early as 12 months of age. The term “spectrum” is associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms over time.

Patients with ASD:

  • face difficulties in social interaction, communication, activities, and nonverbal interactions; and
  • show repetitive patterns of behaviors. ASD patients show high dependency on their routines, high sensitivity to their environment changes, or intense focus on inappropriate items presented before them.
View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Alpha Stockman 1 month ago Member's comment

Good read, thanks.

William K. 1 month ago Member's comment

Quite a serious bit of coverage and analysis in this article. Thanks.

Bill Johnson 1 month ago Member's comment

Agreed. Nice to see.

Terrence Howard 1 month ago Member's comment

Sounds promising.

Joel Santiago 1 month ago Member's comment

When will CannAmide be available outside of Canada?

Adam Reynolds 1 month ago Member's comment

Why is there nothing on SciSparc's website? Unless there is something wrong with my internet, every page is blank except for the homepage, and that is practically blank.

https://scisparc.com

Kurt Benson 1 month ago Member's comment

Thanks for putting $SPRCY on my radar!